Clinical Trials Logo

Vasodilatory Shock clinical trials

View clinical trials related to Vasodilatory Shock.

Filter by:
  • None
  • Page 1

NCT ID: NCT06351150 Not yet recruiting - Vasodilatory Shock Clinical Trials

Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock

Start date: May 2024
Phase: Phase 3
Study type: Interventional

A randomized, double-blind, placebo-controlled study on the treatment of refractory distributed shock with angiotensin II injection, with a random ratio of 1:1. Assuming a success rate of 25% for the main therapeutic endpoint in the control group and 50% for the experimental group, a total of 214 subjects will be enrolled, including 107 in the experimental group and 107 in the control group.

NCT ID: NCT05824767 Recruiting - Septic Shock Clinical Trials

Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock

DARK-Sepsis
Start date: April 17, 2023
Phase: Phase 4
Study type: Interventional

This trial will be a randomized controlled single-center pilot trial comparing the use of angiotensin II versus standard-of-care (SOC) vasopressor therapy in adult patients with persistent vasodilatory shock despite moderate-dose norepinephrine, with a primary outcome of the ability of novel biomarkers (renin and DPP3) to predict blood pressure response to angiotensin II. Given our angiotensin II will be compared to SOC, this will be an unblinded study.

NCT ID: NCT03378466 Terminated - Septic Shock Clinical Trials

Heparin Anticoagulation in Septic Shock

HALO
Start date: March 12, 2018
Phase: Phase 2
Study type: Interventional

This study is a pragmatic open-label international randomized trial comparing therapeutic dose intravenous unfractionated heparin (UFH) to standard care venous thromboprophylaxis in patients diagnosed with septic shock.

NCT ID: NCT03245528 Approved for marketing - Sepsis Clinical Trials

Expanded Access for LJPC-501

Start date: n/a
Phase: N/A
Study type: Expanded Access

The primary objective of the study is to provide access to LJPC-501 for distributive shock patients who remain hypotensive despite receiving fluid and vasopressor therapy.